Lv1
80 积分 2023-11-18 加入
Acquired Resistance to a New Alk Inhibitor, Alectinib in Lung Cancer
5天前
已完结
Abstract 4548: Discovering novel ALK-lung carcinoma therapeutic strategies by identifying combinations with Alectinib from ALK-positive lung carcinoma cell lines
5天前
已关闭
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
2个月前
已完结
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
5个月前
已完结
ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC
6个月前
已关闭
Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells
9个月前
已完结
MET and ALK as Targets for the Treatment of NSCLC
1年前
已关闭
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
1年前
已完结
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228
1年前
已完结
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
1年前
已完结
皖公网安备34019202002308
